27. - 30. Mai 2010
94. Jahrestagung der Deutschen Gesellschaft für Pathologie in Berlin

Abstracts der Beiträge aus dem Institut

KRAS-/BRAF-status in stage III colorectal cancer –correlation with morphological parameters and prognostic impact

Molecular marker for the prognosis of pancreatic carcinoma

Quantitative analysis of centrosomes in breast cancer in correlation to DNA-ploidy and clinicopathological markers

Prolyl-hydroxylase 4 over-expression inhibits tumor growth by stimulating non functional angiogenesis

VEGF-C protects prostate cancer cells from oxidative stress by the activation of mTORC-2 and AKT-1

Tumor progression in mouse mammary carcinoma is associated with expression of VE-cadherin and HIF hydroxylases

DBC1 and FGFR3 expression as indicators of tumor progression and recurrence in superficial bladder cancer

Immunohistochemical expression of EGFR, HB-EGF, CD9 and MAPK in superficial bladder cancer could be marker for recurrence and progression

Expression of the forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma

Aberrations of DNA-copy number and expression of PARK2 and PACRG in cc-RCC: correlation with clinico-pathological parameters and prognosis

Tipping the balance of PHD-2 leads to tumor growth retardation

Habilitation

Im Februar 2010 hat Frau Dr. med. Christiane Jakob ihr Habilitationsverfahren zum Thema "Prognostische und prädiktive Marker beim neoadjuvant behandelten Rektumkarzinom“ erolgreich abgeschlossen.